BPC-157 (15 mg) is a synthetic pentadecapeptide derived from a protein sequence associated with gastric tissue. Supplied as a lyophilized powder in a single research vial, the product is typically verified for identity and purity by HPLC and mass spectrometry.

BPC-157 has been investigated in laboratory settings for its effects on cytoprotection-related endpoints, tissue-repair-related responses, and vascular-related changes in experimental models. The peptide has been observed to remain stable in gastric environments in preclinical work, which has informed interest in oral formulations for controlled experimental use.

BPC-157 (15mg) Key Features & Specs

• Subcategory: Healing & Regenerative Peptides
• Strength: 15 mg
• CAS: 137525-51-0
• Chemical Formula: C₆₂H₉₈N₁₆O₂₂
• Molecular Weight: 1419.5 g/mol
• Peptide Sequence: Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val
• Synonyms: BPC157, Bepecin

The BPC-157 research peptide is offered for controlled laboratory investigation.

For laboratory research use only.

BPC-157 (15mg) Research Uses

Researchers use Body Protection Compound 157 (BPC-157) across a range of experimental systems to better understand how peptides may influence cellular protection- and tissue repair-related responses. Common research areas include:

• Musculoskeletal Models: Tendon, ligament, muscle, and bone injury models where investigators monitor tissue repair patterns and biomechanical strength.
• Gastrointestinal Studies: Models of mucosal injury or inflammation where researchers evaluate tissue integrity and recovery responses.
• Vascular and Circulatory Research: Investigations measuring angiogenesis, vessel remodeling, and circulation changes under stress conditions.
• Neurological and Cellular Studies: Laboratory work exploring nerve-tissue responses and cellular migration involved in repair processes.

Across these models, the BPC-157 peptide has been studied for its effects on cytoprotective activity, connective tissue organization, and vascular signaling. These investigations are largely preclinical and aim to better understand the biological functions of Body Protection Compound 157 rather than establish clinical outcomes.

BPC-157 (15mg) Insights & Observed Findings

Preclinical studies involving BPC-157 have reported a range of experimental observations across animal and cell models:

• Musculoskeletal Injury Experiments: The peptide has commonly been administered at nanogram- to microgram-per-kilogram doses once daily. Researchers studying tendon or ligament injuries in rodents reported changes in collagen organization and mechanical strength compared with untreated control groups.
• Skin Injury and Wound Repair Models: Animal models using similar dose ranges delivered through oral, intragastric, or injected routes observed changes in the rate of tissue-defect closure and alterations in vascular patterns during the healing process.
• Gastrointestinal Studies: Investigators have studied BPC-157 in rodent models of gastric ulcers, intestinal inflammation, and bile-duct injury. These experiments monitored macroscopic tissue-recovery-related changes, mucosal integrity, and inflammatory markers.
• In Vitro Studies: BPC-157 has been examined in fibroblast and endothelial cell cultures at nanomolar concentrations, showing changes in cell migration, cytoskeletal organization, and extracellular-matrix deposition.

Although these findings are frequently cited in BPC-157 research, most of the evidence comes from animal and in vitro experiments. Human data remain limited to early studies and pharmacokinetic investigations, meaning additional research is required to confirm BPC-157-related biological activity and safety.

BPC-157 (15mg) Handling & Storage

• BPC-157 tablets should be stored in a tightly sealed container and kept in a dry environment, protected from light and moisture.
• Maintaining a controlled laboratory storage environment helps preserve the integrity of the peptide contained in each tablet.
• For experimental applications in which tablets are dissolved or dispersed, preparation should be performed with sterile or analytical-grade solvents under clean laboratory conditions.
• Researchers typically keep prepared solutions refrigerated at 2–8 °C and protected from light for use in the same experimental session or as specified by the investigator.
• All unused materials and experimental solutions should be disposed of in accordance with institutional laboratory safety guidelines and applicable chemical-handling regulations.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Siric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-221. doi:10.1007/s10787-006-1531-7
2. Sikiric P. The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. 1999;7(1):1-14. doi:10.1007/s10787-999-0022-z
3. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. doi:10.1016/j.yrtph.2020.104665
4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2010;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
5. Sikiric P, Blagaic AB, Strbe S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals. 2024;17(4):461. doi:10.3390/ph17040461
6. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7